what is luminal a and b breast cancer

Release time ：Nov-11,2024

Breast cancer, a malignant tumor arising in the cells of the breast, is categorized into various subtypes based on their biological properties. Luminal A and Luminal B are two prevalent subtypes, differentiated primarily by the types of specific hormone and growth factor receptors expressed by the tumor cells.

Luminal A breast cancer typically exhibits positivity for estrogen receptor (ER) and/or progesterone receptor (PR), while being negative for human epidermal growth factor receptor 2 (HER2). This subtype is generally less aggressive, with slower growth rates and a favorable response to endocrine therapy, leading to a more favorable prognosis. Consequently, the treatment strategy for Luminal A breast cancer primarily includes surgery, radiotherapy, and endocrine therapy.

In contrast, Luminal B breast cancer may express HER2 in addition to ER and/or PR, or it may have a high Ki-67 index despite being ER and/or PR positive, indicating active cell proliferation. This subtype is more rapidly growing, more invasive, and less responsive to endocrine therapy compared to Luminal A. As a result, treatment plans for Luminal B breast cancer may incorporate chemotherapy and/or HER2-targeted therapy.

For patients diagnosed with Luminal A or Luminal B breast cancer, it is crucial to adhere to their physician's advice, develop a personalized treatment plan, and engage in regular follow-ups. Additionally, maintaining a healthy lifestyle, including a balanced diet, regular exercise, and abstaining from smoking, can contribute to better therapeutic outcomes and overall quality of life.